Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study

ConclusionIn postmenopausal Japanese women with osteoporosis at high fracture risk, abaloparatide for 48  weeks dose-dependently increased LS, TH, and FN BMDs, supporting further investigation with 80 μg abaloparatide for the treatment of osteoporosis in this population.Trial registration numberJapicCTI-132381.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research